Last update 08 May 2025

30S subunit x GluCls

Basic Info

Related Targets
30S subunitGluCls

Related

1
Drugs associated with 30S subunit x GluCls
Ziverdox
Target
30S subunit x GluCls
Mechanism
30S subunit inhibitors [+1]
Active Org.
Topelia Aust Ltd.
Originator Org.
Topelia Aust Ltd.
Active Indication
COVID-19 [+3]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
2
Clinical Trials associated with 30S subunit x GluCls
ACTRN12624000832572
/ CompletedPhase 1
A Phase 1, Single Centre, Open Label, Multiple Dose Study to Investigate the Safety and Pharmacokinetics of Ziverdox in Healthy Volunteers
ACTRN12624000833561
/ CompletedPhase 1
A Phase 1, Single Centre, Open Label, Single Dose, Food Effect, Cross Over Study to Investigate the Safety and Pharmacokinetics of Ziverdox in Healthy Volunteers
100 Clinical Results associated with 30S subunit x GluCls
Login to view more data
100 Translational Medicine associated with 30S subunit x GluCls
Login to view more data
0 Patents (Medical) associated with 30S subunit x GluCls
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free